Armas Pharmaceuticals launches 2 generics
Armas Pharmaceuticals is debuting its generics of Xeloda (capecitabine) and Gleevec (imatinib).
Capecitabine, which is the generic of Hoffman-La Roche’s Xeloda, will be available in strengths of 100 mg and 400 mg.
Imatinib is the generic of Novartis’ Gleevec. It will be available in 150-mg and 500-mg dosage strengths.
"Following the launch of our first oncology injectable, azacitidine for injection, in late 2018, Armas Pharmaceuticals is excited to announce the launch of our first two oral oncology products to the market. Imatinib and capecitabine expands on Armas's goal to bring high quality, affordable pharmaceuticals to the U.S. market," Armas president and CEO John Niemi said.
Capecitabine had a market value of approximately $108 million, while imatinib mesylate, had a market value of approximately $655 million for the year ending Dec. 31, 2018, according to industry sales data.
Capecitabine, which is the generic of Hoffman-La Roche’s Xeloda, will be available in strengths of 100 mg and 400 mg.
Imatinib is the generic of Novartis’ Gleevec. It will be available in 150-mg and 500-mg dosage strengths.
"Following the launch of our first oncology injectable, azacitidine for injection, in late 2018, Armas Pharmaceuticals is excited to announce the launch of our first two oral oncology products to the market. Imatinib and capecitabine expands on Armas's goal to bring high quality, affordable pharmaceuticals to the U.S. market," Armas president and CEO John Niemi said.
Capecitabine had a market value of approximately $108 million, while imatinib mesylate, had a market value of approximately $655 million for the year ending Dec. 31, 2018, according to industry sales data.